Amgen

Pharmalot By Ed Silverman

Pfizer stops developing a cholesterol drug. So who is the big winner?

Biotech By Damian Garde

These pricey cholesterol drugs aren’t selling. And that has the biotech industry sweating

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: FDA approves a biosimilar version of Enbrel

Pharmalot By Ed Silverman

Nonprofit seeks to dispel ‘myths’ about how it assesses drug values

Pharmalot By Ed Silverman

New tools for assessing drug value haven’t caught on with payers — yet

Pharmalot By Ed Silverman

Novartis buries news that the FDA rebuffed its biosimilar drug

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Pharma backs patients, docs who oppose Medicare Part B overhaul

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Are too many companies chasing the same kind of cancer drug?